Stay updated on Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page's revision number was updated from v3.5.3 to v3.5.4, indicating a minor backend/template update that does not change the displayed study details.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check33 days agoChange DetectedThis updates the ClinicalTrials.gov page’s display revision/version in the footer from v3.5.2 to v3.5.3, without changing any study details or record information.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check69 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check76 days agoChange DetectedPage revision updated to v3.4.3 with new dates (2026-03-03, 2026-03-05, 2026-03) and the previous revision v3.4.2 removed.SummaryDifference0.2%

- Check104 days agoChange DetectedA new Revision: v3.4.2 tag appears and the prior government funding lapse notice is removed; the study details and page content remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab ± Azacitidine in MDS Clinical Trial page.